Altimmune, Inc.
ALT
$5.61
-$0.36-6.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 20.00K | 52.00K | 409.00K | 410.00K | 426.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.00K | 52.00K | 409.00K | 410.00K | 426.00K |
| Cost of Revenue | 82.23M | 79.35M | 77.94M | 70.04M | 65.80M |
| Gross Profit | -82.21M | -79.30M | -77.53M | -69.63M | -65.37M |
| SG&A Expenses | 20.97M | 20.21M | 19.75M | 18.92M | 18.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.19M | 99.56M | 97.69M | 88.96M | 83.94M |
| Operating Income | -103.17M | -99.51M | -97.28M | -88.55M | -83.51M |
| Income Before Tax | -95.06M | -103.52M | -101.35M | -92.77M | -88.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.06 | -103.52 | -101.35 | -92.77 | -88.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.06M | -103.52M | -101.35M | -92.77M | -88.45M |
| EBIT | -103.17M | -99.51M | -97.28M | -88.55M | -83.51M |
| EBITDA | -102.93M | -99.19M | -96.88M | -88.08M | -83.03M |
| EPS Basic | -1.34 | -1.55 | -1.62 | -1.59 | -1.64 |
| Normalized Basic EPS | -0.84 | -0.84 | -0.88 | -0.86 | -0.89 |
| EPS Diluted | -1.34 | -1.55 | -1.62 | -1.59 | -1.64 |
| Normalized Diluted EPS | -0.84 | -0.84 | -0.88 | -0.86 | -0.89 |
| Average Basic Shares Outstanding | 284.07M | 271.25M | 253.80M | 233.57M | 212.89M |
| Average Diluted Shares Outstanding | 284.07M | 271.25M | 253.80M | 233.57M | 212.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
